SARS-CoV-2 ADE-Causing Antibody (S9HC)
SARS-CoV-2 ADE-Causing Antibody (S9HC)

ELISA binding of SARS-CoV-2 ADE-Causing Antibody (S9HC) (GenScript, A02133) with recombinant SARS-CoV-2 Spike protein (ECD, His & Flag Tag) (GenScript, Z03481).
Coating antigen: SARS-CoV-2 Spike protein (ECD), 1 µg/ml.
SARS-CoV-2 ADE-Causing Antibody (S9HC) (GenScript, A02133) dilution start from 1 µg/ml.

SARS-CoV-2 ADE-Causing Antibody (S9HC)

Binding assay of SARS-COV-2 (Delta) to ACE2 mediated by antibodies
First, recombinant SARS-CoV-2 Delta spike protein (S1, His Tag) (GenScript, Z03612) was coated on the plate. Then, ADE-Causing antibody (GenScript, A02133), neutralizing antibody (GenScript, A02087) or non-neutralizing antibody (GenScript, A02038) were added to the wells after gradient dilution. Last, HRP conjugated ACE2 protein was added to the well to form the signals.
The result indicated that SARS-CoV-2 ADE-Causing Antibody (S9HC) (A02133) could enhance SARS-CoV-2 Delta spike protein binding with ACE2 compared with A02087 and A02038 which proved the ADE effect.

SARS-CoV-2 ADE-Causing Antibody (S9HC)

GenScript SARS-CoV-2 ADE-Causing Antibody (S9HC) reacts with SARS-CoV-2 Spike protein of wild type and delta variant. It can obviously enhance the SARS-COV-2 binding with ACE2.
A02133
¥64,733.00

Ask us a question
Overview
Specificity GenScript SARS-CoV-2 ADE-Causing Antibody (S9HC) reacts with SARS-CoV-2 Spike protein of wild type and delta variant. It can obviously enhance the SARS-COV-2 binding with ACE2.
Host Species Humanized
Immunogen SARS-CoV-2 Spike protein
Species Reactivity Not applicable
Conjugate Unconjugated

Applications
Working concentrations for specific applications should be determined by the investigator. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Application Recommended Usage
ELISA 0.01-1 µg/ml

Properties
Form Liquid
Storage Buffer PBS, pH 7.2, Azide free
Concentration 1 mg/ml
Endotoxin Level < 10 EU/mg
Storage Instructions Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. Avoid repeated freezing and thawing cycles.
Purification Affinity chromatography
Isotype Recombinant human IgG1
Clonality Monoclonal
Clone ID S9HC

Examples
  • SARS-CoV-2 ADE-Causing Antibody (S9HC)
    • SARS-CoV-2 ADE-Causing Antibody (S9HC)

    ELISA binding of SARS-CoV-2 ADE-Causing Antibody (S9HC) (GenScript, A02133) with recombinant SARS-CoV-2 Spike protein (ECD, His & Flag Tag) (GenScript, Z03481).
    Coating antigen: SARS-CoV-2 Spike protein (ECD), 1 µg/ml.
    SARS-CoV-2 ADE-Causing Antibody (S9HC) (GenScript, A02133) dilution start from 1 µg/ml.

  • SARS-CoV-2 ADE-Causing Antibody (S9HC)
    • SARS-CoV-2 ADE-Causing Antibody (S9HC)

    Binding assay of SARS-COV-2 (Delta) to ACE2 mediated by antibodies
    First, recombinant SARS-CoV-2 Delta spike protein (S1, His Tag) (GenScript, Z03612) was coated on the plate. Then, ADE-Causing antibody (GenScript, A02133), neutralizing antibody (GenScript, A02087) or non-neutralizing antibody (GenScript, A02038) were added to the wells after gradient dilution. Last, HRP conjugated ACE2 protein was added to the well to form the signals.
    The result indicated that SARS-CoV-2 ADE-Causing Antibody (S9HC) (A02133) could enhance SARS-CoV-2 Delta spike protein binding with ACE2 compared with A02087 and A02038 which proved the ADE effect.


Background
Target Background SARS-CoV-2 ADE-causing antibody is a SARS-CoV-2 Spike protein antibody that can exacerbate the COVID-19 disease severity of patients. Antibody-dependent enhancement (ADE) may be involved in the clinical observation of patients with increased severity of symptoms and high levels of SARS-CoV-2 antibodies. It is reported [1] that the same antibodies against the NTD domain of the SARS-CoV-2 spike protein have an ADE effect by increasing the binding of ACE2 to the spike protein.
Synonyms Anti-SARS-CoV-2 ADE-Causing Antibody; SARS-CoV-2 Antibody-dependent enhancement Antibody; SARS-CoV-2 ADE response Antibody; SARS-CoV-2 Spike Antibody; SARS-CoV-2 ADE effect.
Reference [1] Liu Y, Soh W T, Kishikawa J I, et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. 2021.

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.